Swiss pharma giant Novartis (NOVN: VX) and the product development partnership Medicines for Malaria Venture (MMV) have announced positive data from their Phase II/III CALINA study.
The data demonstrate that a novel formulation of Coartem (artemether-lumefantrine) - developed for babies weighing less than 5kg with malaria - has the required pharmacokinetic profile and good efficacy and safety.
This trial was conducted in several African countries. The findings have been submitted for regulatory review.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze